Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

Market Cap	43.69B
Revenue (ttm)	3.72B
Net Income (ttm)	476.19M
Shares Out	1.11B
EPS (ttm)	0.43
PE Ratio	91.17
Forward PE	68.95
Dividend	0.27 (0.69%)
Ex-Dividend Date	Jan 24, 2025

Volume	5,242,059
Average Volume	4,023,827
Open	36.80
Previous Close	38.55
Day's Range	36.80 - 40.32
52-Week Range	25.13 - 40.66
Beta	0.09
RSI	71.01
Earnings Date	Apr 12, 2025

About SHE:002653

Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular. The company was formerly known as Xizang Haisco Pharmaceut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 5,448
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2023, SHE:002653's revenue was 3.36 billion, an increase of 11.27% compared to the previous year's 3.02 billion. Earnings were 295.11 million, an increase of 6.51%.